跳至主要内容
临床试验/NCT00032955
NCT00032955已完成3 期

Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification

University of California, Los Angeles11 个研究点 分布在 1 个国家目标入组 163 人开始时间: 2001年2月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
163
试验地点
11
主要终点
Degree of drug craving

研究概览

简要总结

The purpose of this study is to assess buprenorphine/naloxone versus clonidine for inpatient opiate detoxification.

详细描述

Patients randomized to the BUP/NX arm will receive daily doses for 13 days with sublingual administration of 2 mg buprenorphine/0.5 mg naloxone tablet(s) and/or an 8 mg buprenorphine/2.0 mg naloxone tablet(s). The starting dose on day 1 is 4 mg/1 mg BUP/NX with an additional 4 mg/1 mg, if needed, escalating in a step-wise manner to 16 mg/4 mg BUP/NX on day 3 and tapering to 2 mg/ 0.5 mg BUP/NX by days 12 to 13. Patients randomized to the clonidine arm will receive oral clonidine (0.05 to 0.1 mg depending upon weight) every 4 to 6 hours for 24 hours not to exceed 0.6 mg total on day 1. On day 2, a clonidine transdermal patch will be applied (0.1 mg/day/7-day patch with number of patches adjusted by weight). Oral clonidine will continue to be given on the second day of detoxification and increased to 0.2 mg every 6 hours or 0.1 mg every 3 hours not to exceed 0.8 mg over 24 hours. Patches will be worn all 13 days of detoxification. The dose of clonidine will be adjusted according to the proposed detoxification schedule, patient's weight, tolerance, and systolic blood pressure. Patients will receive counseling according to procedures in existence at each CTP throughout the study. Self-help detoxification handbooks will be distributed to all study participants.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
15 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Treatment-seeking males and non-pregnant and non-lactating females, 15 years and older, who fulfill DSM-IV criteria for opiate dependence, report experiencing symptoms of opiate withdrawal, are currently physically dependent on opioids, and are need of medical assistance for opioid withdrawal.
  • Systolic blood pressure > or = 100mm Hg, and pulse > or = 56 bpm.
  • Good general health or, in case of a medical/psychiatric condition needing ongoing treatment, under the care of a physician willing to continue patient's medical management and cooperate with the study physicians.
  • Agreeable to and capable of signing the informed consent approved by an institutional review board and, if under the age of 18 (excluding emancipated minors), assent and concurrent consent from a parent or legal guardian.
  • Use of one of the following acceptable methods of birth control by female patients of childbearing potential:
  • oral contraceptives
  • barrier (diaphragm or cervical cap) with spermicide or condom
  • intrauterine progesterone contraceptive system
  • levonorgestrel implant
  • medroxyprogesterone acetate contraceptive injection
  • complete abstinence from sexual intercourse

排除标准

  • Medical condition that would make participation, in the opinion of the study physician, medically hazardous (e.g., acute hepatitis, unstable cardiovascular, liver or renal disease);
  • Clinically significant abnormalities in ECG.
  • Known allergy or sensitivity to buprenorphine, naloxone, or clonidine.
  • Receiving beta-blockers, calcium channel blockers, tricyclics, digitalis and other medications which may interact adversely with clonidine.
  • Acute severe psychiatric condition in need of immediate treatment, or imminent suicide risk.
  • Dependence on alcohol, benzodiazepines or other depressants, or stimulants, and requiring immediate medical attention.
  • Participation in an investigational drug study, including buprenorphine, within the past 30 days.
  • Methadone or LAAM maintenance or detoxification within 30 days of enrollment.
  • Pending legal action that could prohibit or interfere with participation.
  • Unable to remain in area for duration of active phase of treatment.
  • Females that are pregnant, lactating, or planning to become pregnant.

结局指标

主要结局

Degree of drug craving

Adverse events

Adverse effect measures

Drug use

Drug craving

Decreased frequency of HIV related behavior

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (11)

Loading locations...

相似试验